## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.2% below STRENGTH zone (4.0-10.0%); PEG 2.50 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (43% of avg).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($80.09)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. GE HealthCare Technologies Inc. $GEHC Shares Acquired by Valicenti Advisory Services Inc.**
- Source: MarketBeat | 20251228T115724 | Bullish | Relevance: 100%
- Valicenti Advisory Services Inc. increased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 22.6% in the third quarter, now holding 68,107 shares valued at $5.12 million. Other institutional investors like Dodge & Cox, Norges Bank, and Holocene Advisors LP have also made significant moves in GEHC shares, with 82.06% of the stock owned by institutional investors. Despite a "Moderate Buy" consensus rating and an average price target of $87.09 from Wall Street analysts, the company's financial performance shows a market cap of $38.1 billion and recent positive quarterly earnings results.

**2. GE HealthCare Technologies Inc. $GEHC Shares Sold by Voya Investment Management LLC**
- Source: MarketBeat | 20251224T141133 | Somewhat-Bullish | Relevance: 100%
- Voya Investment Management LLC decreased its stake in GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 10.8% during the third quarter, while other major institutions like Vanguard, Dodge & Cox, State Street, Geode, and Norges Bank increased their holdings. GE HealthCare reported strong quarterly results, beating EPS and revenue estimates, and announced a modest quarterly dividend. The company maintains a "Moderate Buy" consensus rating from analysts with an average price target of $87.09.

**3. GE HealthCare CEO Peter Arduini is forging a new chapter while drawing on Jack Welch’s legacy**
- Source: Fortune | 20251228T110202 | Bullish | Relevance: 93%
- GE HealthCare CEO Peter Arduini discusses leading the company post-spin-off from General Electric, drawing on GE's legacy and Jack Welch's leadership principles while adapting to modern medical technology and digital health landscapes. He highlights the company's significant increase in R&D investment and focus on lean principles, innovation, and global market strategies, particularly in China. Arduini emphasizes authenticity, communication, and empowering employees to live the company's values in his leadership approach.

**4. Spotting Winners: Hologic (NASDAQ:HOLX) And Medical Devices & Supplies - Imaging, Diagnostics Stocks In Q3**
- Source: TradingView — Track All Markets | 20251225T030749 | Somewhat-Bullish | Relevance: 73%
- This article reviews the Q3 earnings for medical devices & supplies - imaging, diagnostics stocks, highlighting Hologic (NASDAQ:HOLX), QuidelOrtho (QDEL), GE HealthCare (GEHC), and Lantheus (LNTH). The industry faces challenges like high development costs and regulatory hurdles but benefits from consistent demand and technological advancements. Hologic showed strong revenue growth, QuidelOrtho outperformed expectations with a guidance raise, GE HealthCare had good results despite being the "weakest," and Lantheus beat analyst estimates significantly.

**5. Revenue Cycle Management (RCM) Market Overview, Key Growth Factors, and Major Player Analysis**
- Source: openPR.com | 20251224T160945 | Somewhat-Bullish | Relevance: 72%
- The Revenue Cycle Management (RCM) market is projected to reach $273.6 billion by 2029, growing at a CAGR of 15.1%, driven by technological advancements and evolving healthcare models. Key trends include the integration of AI, machine learning, and blockchain, along with a focus on value-based care and patient engagement. The market features significant players like R1 RCM Inc. and McKesson Corporation, with recent strategic acquisitions and technological innovations further shaping its landscape.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-11 | Citigroup | $88 | $83 | +6% |
| 2025-12-11 | Jefferies | $105 | $95 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-11 | Citigroup | main | Neutral |
| 2025-12-11 | Jefferies | main | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 2.50 elevated, pricing in significant growth expectations. Forward P/E 17.0x stretched relative to 8% growth. Quality metrics strong (ROE 24%). Analyst sentiment positive (2 raises, avg +8%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.2B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.50 |
| Forward P/E | 17.0 |
| Current P/E | 18.4 |
| YoY Growth | 8.4% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.9% over 5 days). Below STRENGTH zone by 4.2pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. Volume at 43% of 20MA suggests lack of conviction. OFD pattern: +DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.22% (CS: 51) | Neutral |
| RSI_14 | 58.3 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 1.007x | Above |
| vs SMA50 | 1.066x | Above |
| vs SMA200 | 1.123x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $83.61
- **Stop Loss:** $80.09 (4.2% risk)
- **Target:** $87.13 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 375
- **Position Value:** $31,353.75
- **Portfolio %:** 31.35%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*